Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Fatty Liver Alliance
Homepage:
fattyliver.ca
Alternate name:
Alliance du foie gras
ROR:
01z4ged55
OpenAlex ID:
I4405268761
Works
14
Awards
1
Opportunities and challenges following approval of resmetirom for MASH liver disease
2024
·
Jeffrey V. Lazarus
, Dana Ivancovsky Wajcman
, et al.
·
Nature Medicine
·
64
PDF
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
2026
·
Zobair M. Younossi
, Markos Kalligeros
, et al.
·
Clinical Gastroenterology and Hepatology
·
28
The People-First Liver Charter
2025
·
Jeffrey V. Lazarus
, Dana Ivancovsky Wajcman
, et al.
·
Nature Medicine
·
21
PDF
Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis
2026
·
Zobair M Younossi
, Aleksander Krag
, et al.
·
The Lancet. Gastroenterology & hepatology
·
19
Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care
2025
·
Zobair M. Younossi
, Vincent Wai‐Sun Wong
, et al.
·
Liver International
·
14
PDF
Letter to the Editor: People living with HIV and NAFLD—A population left behind in the global effort for liver fibrosis screening?
2023
·
Giada Sebastiani
, Jovana Milic
, et al.
·
Hepatology
·
5
PDF
Barriers and facilitators to liver fibrosis screening: Perspectives and practices of Canadian primary care physicians
2025
·
Duy A Dinh
, Michael Betel
, et al.
·
Canadian Liver Journal
·
4
PDF
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
2026
·
Zobair M. Younossi
, George Papatheodoridis
, et al.
·
Liver International
·
2
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease
2026
·
Jeffrey V. Lazarus
, Christopher J. Kopka
, et al.
·
Nature Reviews Gastroenterology & Hepatology
·
2
Correction: Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis
2026
·
Jessica Burnside
, Maya Djerboua
, et al.
·
Scientific Reports
PDF
Metabolic dysfunction–associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver
2026
·
Mohit Kehar
, Alnoor Ramji
, et al.
·
Canadian Liver Journal
PDF
Development of a Patient Journey Map for Metabolic Dysfunction–Associated Steatohepatitis: A Comprehensive Assessment of the Patient Journey in North America
2026
·
David O. Garcia
, Roberto A. Calle
, et al.
·
Journal of Patient Experience
Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis
2026
·
Jessica Burnside
, Maya Djerboua
, et al.
·
Scientific Reports
Discrete choice experiments and conjoint analyses in health screening programs for type 2 diabetes and liver disease: a scoping review
2025
·
Felice Cinque
, Clara Long
, et al.
·
Canadian Liver Journal
Show more works
View as search
Works count:
14
Citation count:
159
Year
Topic
Type